Live from the NIH registry
Studies recruiting near Danbury right now
Top 25 of 1,167 recruiting studies, sorted by proximity — each links to its official registry page
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NK-Cell Lymphoma, NK-Cell Leukemia
EARLY/Phase 1
Interventional 40 participants sought
New York Medical College — Valhalla, New York (27.6 mi)
· Sponsor: New York Medical College
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Phase 1
Interventional 210 participants sought
Yale Cancer Center — New Haven, Connecticut (28.9 mi)
· Sponsor: Genentech, Inc.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Phase 1
Interventional 604 participants sought
Smilow Cancer Hospital (Yale University) — New Haven, Connecticut (28.9 mi)
· Sponsor: Revolution Medicines, Inc.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
New York Medical College — Valhalla, New York (27.6 mi)
· Sponsor: National Cancer Institute (NCI)
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Yale University School of Medicine — New Haven, Connecticut (28.9 mi)
· Sponsor: Medtronic MiniMed, Inc.
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Phase 2
Interventional 113 participants sought
New York Medical College at Westchester Medical Center — Valhalla, New York (27.6 mi)
· Sponsor: Anagram Therapeutics, Inc.
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Phase 2
Interventional 20 participants sought
Gastroenterolgy Center of Conneticut — Hamden, Connecticut (29.8 mi)
· Sponsor: Acurx Pharmaceuticals Inc.
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Chin Augmentation
N/A
Interventional 100 participants sought
Galderma Investigational Site # 8680 — Westport, Connecticut (18.9 mi)
· Sponsor: Galderma R&D
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut (17.8 mi)
· Sponsor: SWOG Cancer Research Network
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
N/A
Observational 500 participants sought
Clinical Trial Site — New Haven, Connecticut (28.9 mi)
· Sponsor: Alexion Pharmaceuticals, Inc.
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
N/A
Observational 30 participants sought
Yale School Of Medicine — New Haven, Connecticut (28.9 mi)
· Sponsor: Takeda
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
DaVita Clinical Research — Middlebury, Connecticut (19.8 mi)
· Sponsor: R1 Therapeutics
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut (28.9 mi)
· Sponsor: Relay Therapeutics, Inc.
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Phase 3
Interventional 1,300 participants sought
Yale University School of Medicine — New Haven, Connecticut (28.9 mi)
· Sponsor: Kura Oncology, Inc.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
HNSCC, ESCC
Phase 1
Interventional 150 participants sought
Normunity Investigational Site — New Haven, Connecticut (28.9 mi)
· Sponsor: Normunity AccelCo, Inc.
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1
Interventional 105 participants sought
Yale Cancer Center — New Haven, Connecticut (28.9 mi)
· Sponsor: BeOne Medicines
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Phase 2, Phase 3
Interventional 500 participants sought
New England Institute for Clinical Research (Ki Health Partners) — Stamford, Connecticut (24.3 mi)
· Sponsor: Annovis Bio Inc.
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8
Phase 2
Interventional 16 participants sought
Yale University Cancer Center LAO — New Haven, Connecticut (28.9 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery
Brain Metastasases
Phase 2
Interventional 50 participants sought
Memorial Sloan Kettering Westchester (Limited Protocol Activities) — East White Plains, New York (28.9 mi)
· Sponsor: Memorial Sloan Kettering Cancer Center
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Alzheimers Disease, Dementia
Phase 2, Phase 3
Interventional 280 participants sought
Yale University School of Medicine — New Haven, Connecticut (28.9 mi)
· Sponsor: Washington University School of Medicine
Observational Study Protocol: LIVER-R
Hepatobiliary Cancers
N/A
Observational 4,000 participants sought
Research Site — White Plains, New York (29.6 mi)
· Sponsor: AstraZeneca
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
Lung Cancer Screening
N/A
Observational 409 participants sought
Memorial Sloan Kettering Westchester (All Protocol Activities) — East White Plains, New York (28.9 mi)
· Sponsor: Memorial Sloan Kettering Cancer Center
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
White Plains Hospital Physician Associates — White Plains, New York (29.6 mi)
· Sponsor: SCRI Development Innovations, LLC
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Focal Onset Seizures
Phase 2
Interventional 216 participants sought
Yale University — New Haven, Connecticut (28.9 mi)
· Sponsor: Supernus Pharmaceuticals, Inc.
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
EGFR Inhibitor-associated Rash
Phase 1, Phase 2
Interventional 32 participants sought
Yale University School of Medicine — New Haven, Connecticut (28.9 mi)
· Sponsor: Azitra Inc.